Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
CPhI WW FrankfurtCPhI WW Frankfurt
Not Confirmed
Not Confirmed
28-30 October, 2025
Not Confirmed
Not Confirmed
29 September-02 October, 2025
Not Confirmed
Not Confirmed
29 September-01 October, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI WW FrankfurtCPhI WW Frankfurt
Industry Trade Show
Not Confirmed
28-30 October, 2025
Industry Trade Show
Not Confirmed
29 September-02 October, 2025
Industry Trade Show
Not Confirmed
29 September-01 October, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/50-years-of-innovation-mikart-s-legacy-and-what-s-next-in-cdmo-excellence
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/global-api-micronization-market-set-to-surge-49-by-2030-led-by-specialized-industry-pioneers
15 Sep 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250915439985/en/Spruce-Biosciences-Resumes-Trading-on-the-Nasdaq-Capital-Market
14 Aug 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250814678929/en/Spruce-Biosciences-Announces-Integrated-Long-Term-Clinical-Data-of-Tralesinidase-Alfa-Enzyme-Replacement-Therapy-TA-ERT-Demonstrating-Profound-and-Durable-Efficacy-and-Safety-in-Patients-with-Sanfilippo-Syndrome-Type-B-MPS-IIIB
14 Aug 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250814987753/en/Spruce-Biosciences-Reports-Second-Quarter-2025-Financial-Results-and-Provides-Corporate-Updates
24 Jul 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250724198639/en/Spruce-Biosciences-Announces-Reverse-Stock-Split
22 Jul 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/07/22/3119626/0/en/HMNC-Brain-Health-and-Spruce-Biosciences-Announce-First-Patient-Dosed-in-Phase-2-TAMARIND-Trial-For-Major-Depressive-Disorder.html
12 Jun 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250612996840/en/Spruce-Biosciences-Announces-Conditional-Nasdaq-Approval-to-Resume-Trading-on-the-Nasdaq-Capital-Market
ABOUT THIS PAGE